Literature DB >> 33388822

Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Anna Basińska-Szafrańska1.   

Abstract

PURPOSE: Many harms secondary to benzodiazepine (BZD) dependence force users towards detoxification treatment. However, even strongly motivated patients tolerate the process badly or experience early relapse. The detoxification procedure has not yet been standardized. The objective of this paper is to examine the hypothesis that faulty detoxification routines may have caused some failures.
METHODS: The detoxification approaches found in the literature were compared stage by stage. The review was used to identify possible common, across-the-board systematic errors.
RESULTS: The presented literature review confirms that the widespread divergence in the BZD metabolism rate is effectively neglected during detoxification routines. Without laboratory measurements, these differences, additionally interfered with by auxiliary drugs, undermine not only the scheduled but even the symptom-driven procedures. An initial substitution with a long-acting BZD, although recommended, may lead to over-accumulation. This excess, varying between patients and incompatible with the current tapering stage, may lead to repeated overestimation of the patient's adjustments to reduced doses. Consequently, the patient's good clinical presentation at withdrawal, resulting in a conclusion of detoxification, may actually reflect a persistently high serum BZD concentration. The low-concentration stage, if shifted past the end of treatment, exposes patients to unexpected, unassisted withdrawal crises. With laboratory feedback, these crises, unlike the symptoms related to deficient re-adaptation mechanisms, could be prevented. Moreover, by minimizing the high-concentration phase, time can be saved for properly assisted low-concentration challenges.
CONCLUSION: A customized detoxification procedure driven not only by the intensity of withdrawal symptoms but also by serum BZD monitoring may prevent some failures. As the standard regimen, it would make detoxification from BZDs more reliable and effective.

Entities:  

Keywords:  Benzodiazepines; Concentration monitoring; Detoxification; Over-accumulation; Pharmacokinetics; Relapse; Serum BZD

Year:  2021        PMID: 33388822     DOI: 10.1007/s00228-020-03048-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  86 in total

1.  Benzodiazepine dependence: when abstinence is not an option.

Authors:  Michael Liebrenz; Lukas Boesch; Rudolf Stohler; Carlo Caflisch
Journal:  Addiction       Date:  2010-11       Impact factor: 6.526

Review 2.  Benzodiazepine use, abuse, and dependence.

Authors:  Charles P O'brien
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

3.  The treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome.

Authors:  D A Charney; A M Paraherakis; K J Gill
Journal:  J Clin Psychiatry       Date:  2000-03       Impact factor: 4.384

4.  Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse.

Authors:  Charles M Morin; Lynda Bélanger; Célyne Bastien; Annie Vallières
Journal:  Behav Res Ther       Date:  2005-01

5.  Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group.

Authors:  F G Zitman; J E Couvée
Journal:  Br J Psychiatry       Date:  2001-04       Impact factor: 9.319

6.  Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication.

Authors:  Kieron P O'Connor; André Marchand; Lynda Bélanger; Nicole Mainguy; Pierre Landry; Pierre Savard; Julie Turcotte; Gilles Dupuis; François Harel; Lise Lachance
Journal:  Addict Behav       Date:  2004-05       Impact factor: 3.913

Review 7.  A practical approach to benzodiazepine discontinuation.

Authors:  R L DuPont
Journal:  J Psychiatr Res       Date:  1990       Impact factor: 4.791

8.  Stories of Hell and Healing: Internet Users' Construction of Benzodiazepine Distress and Withdrawal.

Authors:  Alison M Fixsen; Damien Ridge
Journal:  Qual Health Res       Date:  2017-09-09

Review 9.  Withdrawing benzodiazepines in primary care.

Authors:  Malcolm Lader; Andre Tylee; John Donoghue
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 10.  Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.

Authors:  Dimy Fluyau; Neelambika Revadigar; Brittany E Manobianco
Journal:  Ther Adv Psychopharmacol       Date:  2018-02-09
View more
  2 in total

1.  Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-09-13       Impact factor: 2.953

2.  Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2022-09-17       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.